source
- AstraZeneca’s rare disease drug Wainua fails Phase 3, narrowing path to $80 billion sales goalAstraZeneca announced that its rare disease therapy Wainua did not meet its primary endpoints in a Phase 3 trial, ending plans to broaden the drug’s label for transthyretin amyloidosis cardiomyopat…
- Repligen to acquire BioLife Solutions for $1.5 billion, boosting its role in cell therapy preservationRepligen announced a $1.5 billion acquisition of BioLife Solutions, a company whose CryoStor media is used to preserve cell therapies during storage and transport. BioLife’s products are employed…